|
Post by otherottawaguy on May 29, 2024 11:09:54 GMT -5
Didn't see this here but saw it over on IV.
OOG
|
|
|
Post by otherottawaguy on May 29, 2024 11:09:03 GMT -5
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Co
PR Newswire Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Wed, May 29, 2024, 8:45 AM EDT5 min read
In this article: MNKD -1.94% PULM -0.55% Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device.
Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease.
Master service agreement in place for MannKind to provide future iSPERSE™ dry powder drug formulation development services to Pulmatrix.
BEDFORD, Mass., May 29, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD).
(PRNewsfoto/Pulmatrix, Inc.) (PRNewsfoto/Pulmatrix, Inc.) Ted Raad, Chief Executive Officer of Pulmatrix, commented, "MannKind's interest in iSPERSE™ validates the enablement potential of our innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026. We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind's Cricket® device to develop the 1st orally inhaled DHE treatment for acute migraine."
The Company entered into a cross license with MannKind pursuant to which MannKind will grant Pulmatrix a perpetual, royalty free, exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of PUR3100, our proprietary formulation of dihydroergotamine (DHE) with iSPERSE™, and a perpetual, royalty free, non-exclusive license to use MannKind's Cricket inhalation device for the inhaled delivery of any dry powder formulation formulated for the treatment or prevention of neurological disease. As part of the cross-license, the Company will grant MannKind a perpetual, royalty free, exclusive license to formulate iSPERSE™ with clofazimine for inhalation by humans for the treatment or prevention of infection, for the treatment or prevention of nontuberculous mycobacteria lung disease in humans, and with insulin for inhalation by humans for the treatment or prevention of diabetes. We will also grant MannKind a perpetual, royalty free, non-exclusive license to formulate iSPERSE™ for inhalation for the treatment or prevention of endocrine disease and for inhalation for the treatment or prevention of interstitial lung diseases (including IPF, PPF and other related lung diseases) in humans ("ILD").
As part of the transaction, MannKind will assume the lease of our Bedford, Mass., R&D facility along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory. To maintain continuity of iSPERSE™ platform knowledge, MannKind plans to hire some members of the Pulmatrix R&D staff.
The agreements are anticipated to close in July 2024.
About Pulmatrix, Inc. Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat central nervous system ("CNS"), respiratory and other diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for CNS disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes
|
|
|
Post by otherottawaguy on Apr 18, 2024 10:15:52 GMT -5
Attended the in-pers AGM a few years ago and saw the 3rd dosage packaging (12 units) either on an internal video or by looking at the lines that were running (don't remember which possibly due to too many Negronis). The point being that the new dose cartridge had not yet been publicly announced.
Always enjoyed the opportunity to meet in person with other Proboards members for dinner the night before, breakfast at Panera's or Lunch following.
Regards,
OOG
|
|
|
Post by otherottawaguy on Apr 1, 2024 12:05:14 GMT -5
09:58 AM EDT, 04/01/2024 (MT Newswires) -- Liquidia (LQDA) said Monday that a US court has set aside an injunction that had prohibited the US Food and Drug Administration from issuing final approval of Liquidia's amended new drug application for Yutrepia inhalation powder.
Liquidia said Yutrepia was tentatively approved by the FDA in November 2021 to treat pulmonary arterial hypertension. Liquidia amended its NDA in July 2023 so that it could also be used to treat pulmonary hypertension associated with interstitial lung disease.
United Therapeutics (UTHR) sued the FDA to prevent it from approving the amended NDA as its Tyvaso had exclusive rights to treat pulmonary hypertension associated with interstitial lung disease. However, those exclusive rights expired on Sunday, according to Liquidia.
Liquidia said United Therapeutics has appealed the decision to set aside the injunction, and has filed two separate lawsuits seeking new injunctions against Yutrepia.
Representatives for United Therapeutics did not immediately respond to a request for comment from MT Newswires.
|
|
|
Post by otherottawaguy on Apr 1, 2024 12:02:02 GMT -5
LQDA snip : 09:58 AM EDT, 04/01/2024 (MT Newswires) -- Liquidia (LQDA) said Monday that a US court has set aside an injunction that had prohibited the US Food and Drug Administration from issuing final approval of Liquidia's amended new drug application for Yutrepia inhalation powder.
Liquidia said Yutrepia was tentatively approved by the FDA in November 2021 to treat pulmonary arterial hypertension. Liquidia amended its NDA in July 2023 so that it could also be used to treat pulmonary hypertension associated with interstitial lung disease.
United Therapeutics (UTHR) sued the FDA to prevent it from approving the amended NDA as its Tyvaso had exclusive rights to treat pulmonary hypertension associated with interstitial lung disease. However, those exclusive rights expired on Sunday, according to Liquidia.
Liquidia said United Therapeutics has appealed the decision to set aside the injunction, and has filed two separate lawsuits seeking new injunctions against Yutrepia.
Representatives for United Therapeutics did not immediately respond to a request for comment from MT Newswires.
(Started this as a "New" topic)
|
|
|
Post by otherottawaguy on Mar 7, 2024 9:47:35 GMT -5
I am not paying as close attention as I have in the past, has this been discussed on any calls or announcements?
Specifically wondering about Date and Location?
Regards,
OOG
|
|
|
Post by otherottawaguy on Nov 8, 2023 13:32:25 GMT -5
Do you know if there is a 12 Step Program for MNKD investors?
I thought that I could beat the urge to buy more shares, but I am ready to slip and probably should talk to my sponsor...
|
|
|
Post by otherottawaguy on Nov 8, 2023 10:12:58 GMT -5
Sorry folks, unable to listen to call or read transcript. Did MNKD actually announce that they finally made it into the Black without any accounting wizardry?
Regards,
OOG
|
|
|
Post by otherottawaguy on May 25, 2023 9:34:44 GMT -5
Seems to have only been 3 or 4 of us. All Proposals passed.
|
|
|
Post by otherottawaguy on May 25, 2023 9:34:06 GMT -5
otherottawaguy: Will close Shoutbox in 5 min. If you are still here drop a quick note in so we can see who was here. 7 minutes agox otherottawaguy: Not much to discuss. 8 minutes agox otherottawaguy: Meeting is done. 9 minutes agox akemp3000: I cannot access meeting. Don't know why? 13 minutes agox otherottawaguy: Discussing early stage pipeline 14 minutes agox otherottawaguy: Shareprice is down 2.75% sthis morning 14 minutes agox otherottawaguy: Sounds like Mike will be answering a lot of the Q&A 15 minutes agox otherottawaguy: Taling about trial Phase 2/3 Coflazamin??? 17 minutes agox Thundersnow: Mike did not do a presentation this year. 17 minutes agox otherottawaguy: Board agrees 18 minutes agox otherottawaguy: Q: Will mgmt tie compensation to MNKD share price 18 minutes agox otherottawaguy: Q&A 19 minutes agox BD: Oh I see oog got in as "guest" so I guess you don't need the number 22 minutes agox otherottawaguy: Sounds like all of the Proposals have been approved 22 minutes agox otherottawaguy: I tried a Rado number, but not informat 22 minutes agox BD: Has anyone tried just putting in a random number in the correct format? I don't know what the format is (I'm not listening) but just sayin'... 23 minutes agox otherottawaguy: Voting is now closed 23 minutes agox otherottawaguy: Voting is not taking place...lol 24 minutes agox otherottawaguy: Audit Committee - Deloittes 24 minutes agox otherottawaguy: Stockholder vote on Compensation packages 25 minutes agox otherottawaguy: Commensation of Execs 25 minutes agox otherottawaguy: Stock purchase plan to increase by 3M shares 25 minutes agox otherottawaguy: Equity Incentive Plan to Increase by 25 M share 25 minutes agox otherottawaguy: Authorized Shares 400M - 800M 26 minutes agox akemp3000: No start. No music?? 26 minutes agox otherottawaguy: Director Elections being presented 27 minutes agox otherottawaguy: Thanks, am in as guest 27 minutes agox otherottawaguy: I see it now 28 minutes agox otherottawaguy: What link? 28 minutes agox akemp3000: No control number so I entered as guest. Meeting hasn't started 30 minutes agox otherottawaguy: Was hoping someone had a spare. Don't put it here in the chat though... 34 minutes agox otherottawaguy: I have five different proxy cards at home, just not going to be able to get them in next two minutes 34 minutes agox uvula: I needed my control number. If you call your brokerage account they can tell you what it is. (Schwab 800-323-4332) 36 minutes agox otherottawaguy: "Not Using" 41 minutes agox otherottawaguy: Anyone have a control number they are not suing, please PM me 41 minutes agox otherottawaguy: The meeting just let me in log in and is asking for Control Number from the proxi 42 minutes agox otherottawaguy: Mike has taken a couple of questions in the past. 47 minutes agox otherottawaguy: Do we have any burning questions the group would like to ask? 47 minutes agox otherottawaguy: Looks like I can listen on my phone. Does not seem to be asking for a Proxy number to listen as had been suggested earlier 48 minutes agox otherottawaguy: east.virtualshareholdermeeting.com/vsm/web?pvskey=MNKD2023 50 minutes agox otherottawaguy: This is the link to the call, can't verify here at work, seem to be blocked by corporate firewall. 50 minutes agox liane: Yes - miss the Panera meet-up 51 minutes agox otherottawaguy: We usually went to Panera before the meeting... 52 minutes agox otherottawaguy: investors.mannkindcorp.com/events-and-presentations 53 minutes agox cretin11: Wait what?! Not in person? Dang, no wonder I’m the only one here. Can I at least get a bagel and some coffee?! 54 minutes agox otherottawaguy: Shoutbox is open, wish this was in pers in Danbury but such is life... about an hour ago
|
|
|
Post by otherottawaguy on May 25, 2023 9:13:17 GMT -5
It is possible to sign in as guest, use the other tab..,
|
|
|
Post by otherottawaguy on May 25, 2023 8:34:36 GMT -5
Will paste transcript here once call is over.
|
|
|
Post by otherottawaguy on Apr 5, 2023 9:42:53 GMT -5
Class Action???
|
|
|
Post by otherottawaguy on Mar 24, 2023 9:01:10 GMT -5
Any word on this yet? Looked at Corp website and no mention.
Regards,
OOG
|
|
|
Post by otherottawaguy on Mar 1, 2023 16:36:20 GMT -5
Wondering if there has been any mention of it?
When and Where? Looking for a reason for a road trip...
Regards,
OOG
|
|